Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.87 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.87 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.87 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.87 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.87 |
| ▸ | HTR1A | P08908 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | MAOA | P21397 | 1/20 | 0.87 |
| ▸ | DRD1 | P21728 | 1/20 | 0.87 |
| ▸ | ACHE | P22303 | 1/20 | 0.87 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.87 |
| ▸ | PDE4A | P27815 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | HTR2B | P41595 | 1/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.87 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanomeline SCHEMBL6911783 | 1.00 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7616095 | 1.00 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7613627 | 0.99 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7621723 | 0.96 | CHRM1 (0.87) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6907880 | 0.93 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL121046 | 0.93 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| SCHEMBL6913473 | 0.93 | CHRM1 (1.00) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Oxalic Acid SCHEMBL7612877 | 0.92 | CHRM1 (0.86) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL18049053 | 0.92 | CHRM1 (0.98) | CHRM1CHRM4CHRM2CHRM5CHRM3 | |
| Xanomeline SCHEMBL31112303 | 0.92 | CHRM1 (0.98) | CHRM1CHRM4CHRM2CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0734259-B1 | Use of piperidine compounds in the treatment of schizophrenia | NOVO NORDISK AS (DK) | 2002-06-12 | — | — | EP | disclosed |
| US-5773452-A | ALZHEIMER'S DISEASE; COGNITION ACTIVATORS | NOVO NORDISK ALS (DK) | 1998-06-30 | — | — | US | disclosed |
| US-5753683-A | SCHIZOPHRENIA | NOVO NORDISK A/S (DK) | 1998-05-19 | — | — | US | disclosed |
| US-5750541-A | 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION | NOVO NORDISK A/S (DK) | 1998-05-12 | — | — | US | disclosed |
| US-5744489-A | ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS | GREENWOOD BEVERLEY (US) | 1998-04-28 | — | — | US | disclosed |
| US-5712297-A | COGNITION ACTIVATORS; ALZHEIMER*S DISEASE | NOVO NORDISK A/S (DK) | 1998-01-27 | — | — | US | disclosed |
| EP-0788357-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1997-08-13 | — | — | EP | disclosed |
| US-5565475-A | Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives | MUHLHAUSER MARK A (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0734259-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1996-10-02 | — | — | EP | disclosed |
| EP-0732925-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| EP-0384288-B1 | Piperidine compounds and their preparation and use | NOVO NORDISK AS (DK) | 1995-05-24 | — | — | EP | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| US-5328925-A | Alzheimer*s disease | NOVO NORDISK A/S (DK) | 1994-07-12 | — | — | US | disclosed |
| US-5284859-A | Analgesics, Alzheimer's disease | NOVO NORDISK A/S (DK) | 1994-02-08 | — | — | US | disclosed |
| US-5264444-A | Cognition activators | NOVO NORDISK A/S (DK) | 1993-11-23 | — | — | US | disclosed |
| US-5260311-A | Cognition activators, analgesics for sever pain, glaucoma treatment | NOVO NORDISK A/S (DK) | 1993-11-09 | — | — | US | disclosed |
| US-5041455-A | Stimulants of cognitive function in mammals | NOVO NORDISK A/S (DK) | 1991-08-20 | — | — | US | disclosed |
| EP-0384288-A2 | Piperidine compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1990-08-29 | — | — | EP | disclosed |